AUTOTAC Bio
PrivateLast Round
Series B
Mar 1, 2020
Total Funding Raised
$20.8M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
AUTOTAC Bio operates in Healthcare & Life Sciences and is based in Seoul. Its latest recorded funding round was a Series B round in March 2020.
AUTOTAC Bio is a biotechnology company that develops protein target decomposition therapeutics using its proprietary autophagy-targeting chimera (AUTOTAC) platform technology.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
AUTOTAC Bio Comparables
Compare AUTOTAC Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Automera | 89% | |
| PAQ Therapeutics | 85% | |
| Amphista Therapeutics | 83% |
For institutional investors. Book with your work email.
AUTOTAC Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Mar 1, 2020 | ||||
| Series A | Jun 1, 2019 |
For institutional investors. Book with your work email.
AUTOTAC Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Shinhan Venture Investment | Series A, Series B |
| DAYLI Partners | Series B |
| Seoul National University Technology Holdings | Series A |
| Mirae Asset Venture Investment | Series A |
| AJU IB Investment | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 19, 2026
Monthly visitors increased 153% MoM, reaching 1.4K.
- May 2, 2025
Monthly visitors grew 110% MoM, reaching 998.
For institutional investors. Book with your work email.
AUTOTAC Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about AUTOTAC Bio's valuation, stock price, and market status.
Is AUTOTAC Bio a public or private company?
AUTOTAC Bio is a private company.
What is the current stock price of AUTOTAC Bio?
AUTOTAC Bio is a private company, so its shares have no public market price. Caplight tracks AUTOTAC Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is AUTOTAC Bio worth (valuation)?
Valuation information for AUTOTAC Bio is not publicly available.
Can I buy AUTOTAC Bio stock?
AUTOTAC Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was AUTOTAC Bio's last funding round?
AUTOTAC Bio's most recent funding round was Series B on March 1, 2020.
Who are the main investors in AUTOTAC Bio?
Key investors in AUTOTAC Bio include Shinhan Venture Investment, DAYLI Partners, Seoul National University Technology Holdings, Mirae Asset Venture Investment, AJU IB Investment.
Will AUTOTAC Bio IPO soon?
No public IPO plans have been announced for AUTOTAC Bio.
How can I track AUTOTAC Bio secondary market activity?
Caplight tracks bids, offers, and trades in AUTOTAC Bio's shares on secondary markets.